THE National Institute for Health and Care Excellence (NICE) has published its draft recommendations on the use of cannabis-based medicinal products, holding back from recommending cannabidiol (CBD) for epilepsy.
The draft guidance looks at most of the cannabis-based medicinal products for treating intractable nausea and vomiting as a result of chemotherapy, chronic pain, spasticity, and severe treatment-resistant epilepsy.
The UK medicines authority propose eight recommendations for adoption.
Among them, the recommendation around managing severe treatment-resistant epilepsy, were rigorously dependent on sufficient evidence including cost-effectiveness.
Under certain conditions, nabilone was ticked as an add-on treatment for chemotherapy induced nausea and vomitting while Sativex was dismissed for treating spasticity unless part of a clinical trial.
CBD was not recommended for chronic pain - see nice.org.uk.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Aug 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Aug 19
